• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clofibrate in Neonatal Hyperbilirubinemia.

作者信息

Chawla Deepak

机构信息

Department of Pediatrics, Government Medical College Hospital, Chandigarh, India.

出版信息

Indian J Pediatr. 2017 Oct;84(10):735-736. doi: 10.1007/s12098-017-2438-6. Epub 2017 Aug 5.

DOI:10.1007/s12098-017-2438-6
PMID:28779283
Abstract
摘要

相似文献

1
Clofibrate in Neonatal Hyperbilirubinemia.氯贝丁酯与新生儿高胆红素血症
Indian J Pediatr. 2017 Oct;84(10):735-736. doi: 10.1007/s12098-017-2438-6. Epub 2017 Aug 5.
2
[NEONATAL HYPERBILIRUBINEMIA IN PREMATURE INFANTS WITH THE PRESENCE, AT BIRTH, OF SUBCUTANEOUS HEMORRHAGIC EXTRAVASATIONS].[出生时伴有皮下出血性渗出的早产儿的新生儿高胆红素血症]
Pediatria (Napoli). 1964 Oct 31;72:960-79.
3
A REAPPRAISAL OF EXTRACTION METHODS FOR BILIRUBIN ASSAY AND OF THE ROLE OF BILIRUBIN MONOGLUCURONIDE IN NEONATAL HYPERBILIRUBINEMIA.胆红素测定提取方法的重新评估以及胆红素单葡萄糖醛酸酯在新生儿高胆红素血症中的作用
Pediatrics. 1964 Sep;34:418-9.
4
The effect of clofibrate on hyperbilirubinemia of term neonates.氯贝丁酯对足月儿高胆红素血症的影响。
Acta Med Iran. 2012;50(1):21-5.
5
[CORTISONE DERIVATIVES IN NEONATAL HYPERBILIRUBINEMIA].[新生儿高胆红素血症中的可的松衍生物]
Minerva Nipiol. 1964 Mar-Apr;14:27-34.
6
Clofibrate as an Adjunct to Phototherapy for Unconjugated Hyperbilirubinemia in Term Neonates.氯贝丁酯辅助光疗治疗足月新生儿非结合高胆红素血症。
Indian J Pediatr. 2017 Oct;84(10):763-767. doi: 10.1007/s12098-017-2360-y. Epub 2017 May 17.
7
[Clofibrate for the treatment of hyperbilirubinemia in neonates born at term: a double blind controlled study (author's transl)].
Arch Fr Pediatr. 1981 Dec;38 Suppl 1:867-73.
8
Strategies for neonatal hyperbilirubinemia: a literature review.新生儿高胆红素血症的治疗策略：文献综述
MCN Am J Matern Child Nurs. 2013 Nov-Dec;38(6):377-82;quiz 383-4. doi: 10.1097/NMC.0b013e3182a1fb7a.
9
[CONSIDERATIONS ON NEONATAL HYPERBILIRUBINEMIAS IN PREMATURE TWINS WITH PARTICULAR REFERENCE TO EXCHANGE TRANSFUSION].[关于早产双胞胎新生儿高胆红素血症的思考，特别提及换血疗法]
Minerva Nipiol. 1965 Jul-Aug;15:192-4.
10
[Preventive treatment of jaundice in premature newborn infants with clofibrate. Double-blind controlled therapeutic trial].
Arch Fr Pediatr. 1985 Nov;42(9):759-63.

引用本文的文献

1
Editor's Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner.编辑亮点：氯贝丁酸酯通过依赖 PPARα 的方式增加胆汁酸的胆肠排泄从而降低雄性小鼠肝脏中的胆汁酸。
Toxicol Sci. 2017 Dec 1;160(2):351-360. doi: 10.1093/toxsci/kfx191.

本文引用的文献

1
Clofibrate as an Adjunct to Phototherapy for Unconjugated Hyperbilirubinemia in Term Neonates.氯贝丁酯辅助光疗治疗足月新生儿非结合高胆红素血症。
Indian J Pediatr. 2017 Oct;84(10):763-767. doi: 10.1007/s12098-017-2360-y. Epub 2017 May 17.
2
Clofibrate in combination with phototherapy for unconjugated neonatal hyperbilirubinaemia.氯贝丁酯联合光疗治疗新生儿非结合性高胆红素血症。
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD009017. doi: 10.1002/14651858.CD009017.pub2.
3
Neonatal jaundice: summary of NICE guidance.新生儿黄疸：英国国家卫生与临床优化研究所（NICE）指南总结
BMJ. 2010 May 19;340:c2409. doi: 10.1136/bmj.c2409.
4
Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications.孕龄≥35周新生儿的高胆红素血症：澄清后的最新情况
Pediatrics. 2009 Oct;124(4):1193-8. doi: 10.1542/peds.2009-0329. Epub 2009 Sep 28.
5
Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.经皮肤涂抹后对FVB/Tg.AC小鼠进行氯贝丁酯致癌潜力评估——第二部分。
Int J Toxicol. 2005 Sep-Oct;24(5):327-39. doi: 10.1080/10915810500208199.
6
Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.氯贝丁酯在rasH2小鼠中的致癌潜力评估。
Int J Toxicol. 2005 Sep-Oct;24(5):301-11. doi: 10.1080/10915810500210278.
7
WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.
Lancet. 1984 Sep 15;2(8403):600-4.